Compare Biogen Inc (BIIB) vs Open Text Corporation (OTEX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Open Text Corporation — how do they compare? Biogen Inc trades at $192.5 (market cap $28.34B), while Open Text Corporation trades at $22.65 (market cap $5.40B). The key difference: Biogen Inc is far larger — about 5.2× Open Text Corporation's market cap, and Open Text Corporation pays a 4.9% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | OTEX | |
|---|---|---|
Market Cap | $28.34B | $5.40B |
Sector | Health | Technology |
52-Week High | $216.63 | $39.69 |
52-Week Low | $122.68 | $20.01 |
Enterprise Value | $30.62B | $10.56B |
Dividend Yield | — | 4.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
OpenText (OTEX) trades at $23.57, up 2.43% on the day, with a bullish technical signal from moving averages. The company shows strong profitability with a 73.06% gross margin and has beaten earnings estimates for the last three quarters. Recent strategic moves include a $105 million investment in European AI and cloud expansion and the divestiture of the non-core Vertica business.
The outlook is positive, supported by a consensus analyst price target of $29.75, implying significant upside. Key opportunities include margin expansion and AI-driven growth, while risks involve integration of strategic shifts and competitive pressures in the enterprise software market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →
